Merck, Inc.
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
- Conditions
- Hodgkin Lymphoma
- Interventions
- Radiation: Radiotherapy (RT)Drug: prednisone/prednisolone
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 340
- Registration Number
- NCT03407144
- Locations
- 🇺🇸
University of Chicago ( Site 0066), Chicago, Illinois, United States
🇺🇸Cohen Children's Medical Center of New York ( Site 0052), New Hyde Park, New York, United States
🇺🇸Columbia University/Herbert Irving Cancer Center ( Site 0063), New York, New York, United States
Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)
- Conditions
- Advanced Melanoma
- Interventions
- Biological: pembrolizumab
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1
- Registration Number
- NCT03407170
- Locations
- 🇺🇸
Massachusetts General Hospital ( Site 0102), Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute ( Site 0101), Boston, Massachusetts, United States
Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)
- Conditions
- Solid TumorPharmacokineticsCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2018-01-11
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 184
- Registration Number
- NCT03396445
- Locations
- 🇺🇸
Florida Cancer Specialists ( Site 0002), Sarasota, Florida, United States
🇮🇱Soroka Medical Center-Oncology ( Site 0012), Be'er Sheva, Israel
🇺🇸The West Clinic, P.C. ( Site 0021), Germantown, Tennessee, United States
Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT03382600
- Locations
- 🇯🇵
Kanagawa Cancer Center ( Site 0003), Yokohama, Kanagawa, Japan
🇯🇵Chiba Cancer Center ( Site 0012), Chiba, Japan
🇯🇵National Hospital Organization Shikoku Cancer Center ( Site 0024), Matsuyama, Ehime, Japan
Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)
- Conditions
- HCV Infection
- Interventions
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 57
- Registration Number
- NCT03379506
- Locations
- 🇺🇸
University of California San Francisco ( Site 0020), San Francisco, California, United States
🇺🇸Children's Hospital and Regional Medical Center ( Site 0017), Seattle, Washington, United States
🇺🇸Children's Center for Advanced Pediatrics ( Site 0204), Atlanta, Georgia, United States
Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 116
- Registration Number
- NCT03374254
- Locations
- 🇺🇸
Seattle Cancer Care Alliance ( Site 0104), Seattle, Washington, United States
🇺🇸Rutgers Cancer Institute of New Jersey ( Site 0107), New Brunswick, New Jersey, United States
🇨🇦Princess Margaret Cancer Centre ( Site 0122), Toronto, Ontario, Canada
Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 33
- Registration Number
- NCT03364049
- Locations
- 🇰🇷
Severance Hospital Yonsei University Health System ( Site 0103), Seoul, Korea, Republic of
🇮🇱Chaim Sheba Medical Center. ( Site 0301), Ramat-Gan, Israel
🇨🇦Princess Margaret Hospital.. ( Site 0130), Toronto, Ontario, Canada
Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)
- Conditions
- Neuromuscular Blockade
- Interventions
- First Posted Date
- 2017-11-24
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 288
- Registration Number
- NCT03351608
- Locations
- 🇺🇸
West Virginia University ( Site 0043), Morgantown, West Virginia, United States
🇺🇸Lucille Packard Children's Hospital ( Site 0006), Palo Alto, California, United States
🇺🇸Children's National Medical Center ( Site 0008), Washington, District of Columbia, United States
Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002)
- First Posted Date
- 2017-11-24
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT03351699
- Locations
- 🇩🇪
Charite Research Organisation GmbH ( Site 0001), Berlin, Germany
Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)
- Conditions
- Neuromuscular Blockade
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 207
- Registration Number
- NCT03346070
- Locations
- 🇺🇸
Robert Wood Johnson University Hospital ( Site 2037), New Brunswick, New Jersey, United States
🇺🇸Cleveland Clinic Foundation ( Site 2031), Cleveland, Ohio, United States
🇺🇸Hermann Drive Surgical Center ( Site 2020), Houston, Texas, United States